CCM
MRNA icon

Cutter Capital Management’s Moderna MRNA Stock Holding History

Cutter Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-197,500
Closed -$8.21M – 26
2024
Q4 		$8.21M Buy
+197,500
New +$9.44M 3.37% 15

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cutter Capital Management's MRNA Position: Q1 2025 in Review

Cutter Capital Management sold out of Moderna (MRNA) in Q1 2025, closing a stake of 197,500 shares — an estimated $8.21M sold.

Cutter Capital Management first reported a position in MRNA in Q4 2024 and held it in 1 quarter. The position peaked at $8.21M in Q4 2024. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • Cutter Capital Management reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • Cutter Capital Management sold 197,500 Moderna shares in Q1 2025, an estimated $8.21M.
  • Cutter Capital Management first reported a position in Moderna in Q4 2024 and held it in 1 quarter.
  • Cutter Capital Management's Moderna position peaked at $8.21M in Q4 2024.
  • 693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Cutter Capital Management's 13F filing for Q1 2025, filed 15 May 2025.